a, Migration of THP-1 monocytes through transwell(5 μm pore) to supernatants from control (‘live’) or Fas-induced apoptotic murine thymocytes, thymocytes pre-treated with caspase inhibitor (zVAD-fmk), apoptotic cell supernatants with apyrase, heat-inactivated apyrase or phospholipase D. The fraction of input monocytes that migrated to the lower chamber is shown. b, Attraction of monocytesby Jurkat T cell supernatants collected at the indicated times after apotosis induction via UV or anti-Fas for the indicated times. c, Monocyte attraction was inhibited by pre-treatment of Jurkat cells with zVAD-fmk prior to UV or anti-Fas treatment. d, Schematic for testing recruitment of leukocytes by apoptotic cell supernatants in the mouse air-pouch model. e, Recruitment to the air-pouch of macrophages and monocytes (CD11b+/Gr-1low) or neutrophils (CD11b+/Gr-1high) 24 hrs after injection of apoptotic cell supernatants. Eight mice per group, *p=0.02. f, Monocyte/macrophage and neutrophil populations recruited to the air-pouch 24 hrs after injection of LPS (1 μg) or apoptotic supernatants. Results are the average of six (LPS) and nine (apoptotic supernatant) mice. g, h, and i, Treatment of apoptotic cell supernatants with apyrase inhibits attraction of monocytes in vitro (g) or in the air-pouch model in vivo (h, i), but does not affect monocyte migration to the chemokine CCL2 (250 ng). Five (h) or three (i) mice per group, *p=0.005. j, k, Migration of monocytes to supernatants from apoptotic Jurkat or MCF-7/caspase-3 cells, supernatants being treated with apyrase or PLD. l, (right) CD39 surface expression on transfected Jurkat cells, and (left) monocyte migration to supernatants from CD39-overexpressing cells after UV treatment. Error bars indicate s.e.m.